AI
AVIR icon

Acuitas Investments’s Atea Pharmaceuticals AVIR Stock Holding History

Acuitas Investments’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-323,542
Closed -$1.08M – 73
2024
Q3 		$1.08M Buy
323,542
+64,253
+25% +$233K 0.48% 73
2024
Q2 		$858K Buy
259,289
+1,379
+0.5% +$5.14K 0.46% 76
2024
Q1 		$1.04M Buy
257,910
+86,812
+51% +$340K 0.53% 67
2023
Q4 		$615K Buy
171,098
+47,671
+39% +$144K 0.32% 91
2023
Q3 		$370K Sell
123,427
-3
-0% -$10 0.22% 96
2023
Q2 		$462K Buy
+123,430
New +$462K 0.27% 90

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acuitas Investments's AVIR Position: Q4 2024 in Review

Acuitas Investments sold out of Atea Pharmaceuticals (AVIR) in Q4 2024, closing a stake of 323,542 shares — an estimated $1.08M sold.

Acuitas Investments first reported a position in AVIR in Q2 2023 and held it in 6 quarters. The position peaked at $1.08M in Q3 2024. 106 funds tracked by Wall St. Rank hold AVIR as of Q4 2024.

  • Acuitas Investments reported no remaining Atea Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Acuitas Investments sold 323,542 Atea Pharmaceuticals shares in Q4 2024, an estimated $1.08M.
  • Acuitas Investments first reported a position in Atea Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Acuitas Investments's Atea Pharmaceuticals position peaked at $1.08M in Q3 2024.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2024.

Based on Acuitas Investments's 13F filing for Q4 2024, filed 31 Jan 2025.